CQV Considerations for Single-Use Systems in Biopharmaceutical Manufacturing: A Practical Framework.

Authors

Gurinderpal Singh

Published in

PDA journal of pharmaceutical science and technology. Aug 31, 2026. Epub Aug 31, 2026.

Abstract

Single-use systems (SUS) have become the dominant technology across the biotechnology and pharmaceutical industry, and viral vector manufacturing is no exception. The standard CQV framework, however, was designed and largely developed for stainless steel, fixed-equipment biopharmaceutical manufacturing. This creates real qualification gaps that the industry is currently solving inconsistently. This article proposes a structured, fit-for-purpose CQV approach built around three pillars specific to single-use Biopharmaceutical facilities: equipment qualification of single-use systems, supplier qualification as the foundation of SUS CQV, and a event-driven requalification strategy for single-use multi-product facilities. The framework is illustrated through a detailed qualification example for a single-use bioreactor and is positioned against the current regulatory landscape, including EU GMP Annex 1, 21 CFR 211.65, PDA Technical Report No 66 and FDA gene therapy CMC guidance.

PMID:
42674828
Bibliographic data and abstract were imported from PubMed on 01 Sep 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.